SE9701228D0 - Recombinant protein C and protein S variants - Google Patents

Recombinant protein C and protein S variants

Info

Publication number
SE9701228D0
SE9701228D0 SE9701228A SE9701228A SE9701228D0 SE 9701228 D0 SE9701228 D0 SE 9701228D0 SE 9701228 A SE9701228 A SE 9701228A SE 9701228 A SE9701228 A SE 9701228A SE 9701228 D0 SE9701228 D0 SE 9701228D0
Authority
SE
Sweden
Prior art keywords
protein
component
wild
amino acid
variants
Prior art date
Application number
SE9701228A
Other languages
Swedish (sv)
Inventor
Bjoern Dahlbaeck
Original Assignee
Bjoern Dahlbaeck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bjoern Dahlbaeck filed Critical Bjoern Dahlbaeck
Priority to SE9701228A priority Critical patent/SE9701228D0/en
Publication of SE9701228D0 publication Critical patent/SE9701228D0/en
Priority to JP54152998A priority patent/JP2002501373A/en
Priority to NZ337800A priority patent/NZ337800A/en
Priority to CA002283934A priority patent/CA2283934A1/en
Priority to PCT/SE1998/000490 priority patent/WO1998044000A1/en
Priority to EP98915077A priority patent/EP0996637A1/en
Priority to AU69345/98A priority patent/AU741798B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention is concerned with a variant blood coagulation component, which is substantially homologous in amino acid sequence to wild-type blood coagulation component capable of expressing anticoagulant activity in the protein C-anticoagulant system of blood and selected from protein C (PC), activated protein C (APC) and protein S (PS), said variant component being capable of expressing an anticoagulant activity, which is enhanced in comparison with the anticoagulant activity expressed by the corresponding wild-type blood coagulation component, and said variant component differing from the respective wild-type component, in that it contains in comparison with the said wild-type component at least one amino acid residue modification in its amino acid residue sequence. The present invention is also concerned with methods to produce such variants based on DNA technology, DNA segments intended for use in the said methods, and the use of the said variants for therapeutic and diagnostic purposes.
SE9701228A 1997-04-03 1997-04-03 Recombinant protein C and protein S variants SE9701228D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE9701228A SE9701228D0 (en) 1997-04-03 1997-04-03 Recombinant protein C and protein S variants
JP54152998A JP2002501373A (en) 1997-04-03 1998-03-18 Recombinant protein C and protein S variants
NZ337800A NZ337800A (en) 1997-04-03 1998-03-18 Recombinant protein C and protein S variants
CA002283934A CA2283934A1 (en) 1997-04-03 1998-03-18 Recombinant protein c and protein s variants
PCT/SE1998/000490 WO1998044000A1 (en) 1997-04-03 1998-03-18 Recombinant protein c and protein s variants
EP98915077A EP0996637A1 (en) 1997-04-03 1998-03-18 Recombinant protein c and protein s variants
AU69345/98A AU741798B2 (en) 1997-04-03 1998-03-18 Recombinant protein C and protein S variants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9701228A SE9701228D0 (en) 1997-04-03 1997-04-03 Recombinant protein C and protein S variants

Publications (1)

Publication Number Publication Date
SE9701228D0 true SE9701228D0 (en) 1997-04-03

Family

ID=20406428

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9701228A SE9701228D0 (en) 1997-04-03 1997-04-03 Recombinant protein C and protein S variants

Country Status (7)

Country Link
EP (1) EP0996637A1 (en)
JP (1) JP2002501373A (en)
AU (1) AU741798B2 (en)
CA (1) CA2283934A1 (en)
NZ (1) NZ337800A (en)
SE (1) SE9701228D0 (en)
WO (1) WO1998044000A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
US6841371B2 (en) 2000-02-02 2005-01-11 Eli Lilly And Company Protein C derivatives
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
JP2005518801A (en) * 2002-03-01 2005-06-30 テイ・エイ・シー・スロムボシス・アンド・コアグラシヨン・アクテイエボラーク Recombinant protein C variant
AU2003232176A1 (en) * 2002-06-14 2003-12-31 Maxygen Aps Protein c variants with altered properties
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE464135B (en) * 1989-07-14 1991-03-11 Kabivitrum Ab PROCEDURE FOR DETERMINING THE FUNCTIONAL ACTIVITY OF FREE PROTEIN S OR PROTEIN C IN A PLASMA TEST
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5405946A (en) * 1992-12-02 1995-04-11 The Scripps Research Institute Recombinant protein S variants deficient in C4BP binding activity, compositions and therapeutic methods
JPH08511948A (en) * 1993-06-30 1996-12-17 リークスウニフエルジタイト・ライデン Protein S deficient mutant lacking C4BP binding activity but having APC cofactor activity, composition and therapeutic method

Also Published As

Publication number Publication date
CA2283934A1 (en) 1998-10-08
WO1998044000A1 (en) 1998-10-08
AU6934598A (en) 1998-10-22
AU741798B2 (en) 2001-12-13
JP2002501373A (en) 2002-01-15
NZ337800A (en) 2001-03-30
EP0996637A1 (en) 2000-05-03

Similar Documents

Publication Publication Date Title
RU95115239A (en) Erythropoietin analog
DE69934967D1 (en) METHOD FOR REDUCING IMMUNOGENICITY OF PROTEINS
ATE380867T1 (en) LACTOFERRIN RECEPTOR GENE FROM MORAXELLA
ATE451390T1 (en) POLYPEPTIDES TO BIND TO B-LYMPHOCYTE-STIMULATORY PROTEIN (BLYS)
SE8902532D0 (en) DETERMINATION OF PLASMA PROTEINS
DE3587875D1 (en) RECOMBINANT METHOD FOR THE PRODUCTION OF SERINE PROTEASE INHIBITORS, AND DNA SEQUENCES THEREFOR.
NO881670L (en) DIAGNOSTIC TEST FOR PLASMINOGEN ACTIVATOR INHIBITOR OF TISSUE AND UROKINAS TYPE, AND GENES CODING FOR THE INHIBITOR.
BR9811592A (en) Cytokinin oxidase
SE9701228D0 (en) Recombinant protein C and protein S variants
WO2002010357A3 (en) Gsk3 polypeptides
WO1998011234A3 (en) Human protein kinases
WO2005017188A3 (en) Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
DE69132889D1 (en) SUPERIOR THROMBOMODULIN ANALOGS FOR PHARMACEUTICAL USE
WO2002034915A3 (en) Preferred segments of neural thread protein and methods of using the same
WO2003073980A3 (en) Recombinant protein c variants
ATE510911T1 (en) PROTHROMBIN ACTIVATE PROTEIN
DE69333304D1 (en) INCREASED PRODUCTION OF SECRETED PROTEINS BY RECOMBINANT EUKARYOTIC CELLS
DE69738600D1 (en) NEUROACTIVE PEPTIDES
DE69826717D1 (en) TARGET FOR TREATING ATHEROSCLEROSIS, OBESITY AND DIABETIS TYPE II
DK0616642T3 (en) Novel thrombin inhibitory proteins from terrestrial blood vessels
BRPI0308978A8 (en) active synthetic peptide fragments
ATE312914T1 (en) RDGB PROTEINS
WO2002088180A3 (en) Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds
KR950003312A (en) Chondrocyte protein
WO2004099408A8 (en) Novel protein and dna coding for the same